Navigation Links
Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
Date:11/24/2008

on (CRO).

NOTE: Office Blood Pressure Measurements (OBPMs) were performed by a health care professional during a patient's visit to the treatment center using a standard technique and equipment (i.e. a sphygmomanometer). OBPMs were performed in the morning and the time between intake of study-drug and measurement of OBPM was between 2 and 4 hours.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development and pre-commercialization activities for naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents for the treatment of the signs and symptoms of osteoarthritis. Naproxcinod has completed three pivotal phase 3 studies with positive results and the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) is projected for mid-2009.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the NYSE Euronext Paris (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statemen
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

13611

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
4. CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
7. NewCardio Announces Positive Results From Third Clinical Validation Study
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
11. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Kalifornien, 28. August 2014 ... Start der Patientenrekrutierung für eine IDE-Pivot-Studie ... zur Beurteilung der Sicherheit und Wirksamkeit ... Aneurysmen („WEB") bekanntgegeben. Adam Arthur, MD, Dozent ... of Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der ...
(Date:8/28/2014)... ALISO VIEJO, Calif. , Aug. 28, 2014 ... has initiated patient enrollment in an Investigational Device ... and effectiveness of the WEB™ Aneurysm Embolization System ... University of Tennessee Department of Neurosurgery/Semmes-Murphey Clinic and ... first four patients in the study, treating them with ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
Breaking Medicine Technology:Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3
... GNVC ) announced that Adel A.F. Mahmoud, M.D., ... the Company,s Board of Directors at its annual meeting of ... "Drs. Mahmoud and Connor bring a wealth of experience, especially ... expand the breadth and scope of our vaccine programs there ...
... June 22, 2011 Genesis Biopharma, Inc. (OTC/BB: GNBP), ... that it will hold a conference call with the ... Eastern (9:00 a.m. Pacific).  The Company,s Chairman and Chief ... on the business, and discuss the clinical and commercial ...
Cached Medicine Technology:GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 2GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 3GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 4Genesis Biopharma to Hold Business Update Conference Call on June 29 2
(Date:8/28/2014)... TX (PRWEB) August 28, 2014 After ... Dr. Paul Vitenas is excited to announce the ... of its kind in any city, Mirror Mirror Beauty ... building. , Situated on the corner of Richmond and ... modern architecture, luxurious amenities, and cutting-edge technology in a ...
(Date:8/28/2014)... Having greater amounts of yellow pigment in your eyes ... hazy conditions, a new study reports. In a ... in order to test the distance vision of people ... pigment) in their eyes. The volunteers had widely ... the nutrients lutein and zeaxanthin, according to the researchers, ...
(Date:8/28/2014)... The Foundation for Women’s Cancer ... September by alerting women to the link between obesity ... symptoms of endometrial cancer. , Endometrial cancer is ... common cancer. More than 52,600 will learn of a ... women with weight management challenges to know the early ...
(Date:8/28/2014)... Diego, CA (PRWEB) August 28, 2014 Vitals, ... has named Dr. Sabrina Fabi of Cosmetic Laser Dermatology one ... allows hundreds of thousands of patients to share their doctor ... including bedside manner, face time, and follow-ups. The Vitals Top ... in California, Dr. Fabi was ranked one of the highest ...
(Date:8/28/2014)... 28, 2014 Dr. Bryan McIntosh of ... ebook guide to the tummy tuck cosmetic procedure, ... the procedure itself, and how to recover well afterwards. ... explanations. Dr. McIntosh also discusses how to have accurate ... that the procedure is as successful as possible. , ...
Breaking Medicine News(10 mins):Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Foundation for Women's Cancer Alerts Women to Link Between Obesity and Endometrial Cancer 2Health News:Dr. Sabrina Fabi of Cosmetic Laser Dermatology Recognized as Vitals Top 10 Doctor 2Health News:The Ultimate Guide to the Tummy Tuck Surgery eBook is Released by Dr. Bryan McIntosh 2
... networks begin with one altruistic living donor, study explains, ... one healthy young man stepped forward, willing to give ... years later, 10 people had received new kidneys from ... donation started the first nonsimultaneous, extended altruistic-donor (NEAD) chain. ...
... report finds , , WEDNESDAY, March 11 (HealthDay News) -- Thousands ... by atmospheric ozone, a new study finds. , The greatest ... such as Los Angeles, which has one of the highest ... 25 percent to 30 percent higher annual risk of dying ...
... The Coalition for Ethical Imaging (CEI), a grassroots ... in Texas, has announced its support for Senate Bill ... bill in the House, House Bill 2599 by Rep. ... patient care and safety in the state of Texas ...
... BALTIMORE, March 11 The Open Society Institute,s Closing ... exist for the new Director of the Office of ... the United States, approach to the problem of addiction. ... Gil Kerlikowske,s official nomination as the nation,s "drug czar," ...
... Kidney Month Briefing Reveals Majority of New Kidney Failure ... Disproportionate Rates -WASHINGTON, March 11 Kidney Care Partners ... dialysis professionals, care providers and manufacturers working together to ... disease and kidney failure -- in partnership with the ...
... The American Association of Oral and Maxillofacial Surgeons ... on her recent introduction of H.R. 1339, the ... , which would require insurance plans, including those which ... (ERISA) , that provide surgical benefits, to cover reconstructive ...
Cached Medicine News:Health News:Living Kidney Donation Chains May Help More Get Transplants 2Health News:Living Kidney Donation Chains May Help More Get Transplants 3Health News:Ozone Pollution Taking Toll on American Lives 2Health News:Ozone Pollution Taking Toll on American Lives 3Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 2Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 3Health News:Closing the Addiction Treatment Gap Initiative Highlights Opportunities for New 'Drug Czar' 2Health News:Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease 'Hot Spots' 2Health News:Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease 'Hot Spots' 3Health News:Oral and Maxillofacial Surgeons Applaud Congresswoman McCarthy's Legislation to Require Insurance Coverage for Children With Congenital Deformities 2Health News:Oral and Maxillofacial Surgeons Applaud Congresswoman McCarthy's Legislation to Require Insurance Coverage for Children With Congenital Deformities 3
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
... 50 analyzer is an ... offices and smaller laboratories ... of state-of-the-art instrument-based testing ... efficient way to obtain ...
... Hemoglobin Test Systems provide ... quantitative hemoglobin results with ... a large hematology analyzer. ... of either the B-Hemoglobin ...
... a qualitative immunoassay for urinary albumin that ... This albumin specific, CLIA Waived test has ... of 95%, and gives accurate results in ... up to 8 hours. Since early detection ...
Medicine Products: